{"id":"methotrexate-capsules","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Myelosuppression (anemia, leukopenia, thrombocytopenia)"},{"rate":"10-20","effect":"Mucositis"},{"rate":"10-20","effect":"Nausea and vomiting"},{"rate":"5-15","effect":"Hepatotoxicity"},{"rate":"5-10","effect":"Nephrotoxicity"},{"rate":"5-10","effect":"Alopecia"},{"rate":"5-15","effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting dihydrofolate reductase, methotrexate prevents the conversion of dihydrofolate to tetrahydrofolate, disrupting one-carbon transfer reactions essential for nucleotide synthesis. This leads to suppression of rapidly dividing cells, including cancer cells and activated immune cells. At lower doses, it also has immunosuppressive and anti-inflammatory effects through adenosine release and other mechanisms.","oneSentence":"Methotrexate inhibits dihydrofolate reductase, blocking the synthesis of purines and pyrimidines required for DNA replication and cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:02.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"Breast cancer"},{"name":"Lung cancer"},{"name":"Rheumatoid arthritis"},{"name":"Psoriasis"}]},"trialDetails":[{"nctId":"NCT07477457","phase":"PHASE2","title":"A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-03-11","conditions":"Osteosarcoma, Metastasis","enrollment":45},{"nctId":"NCT03970096","phase":"PHASE2","title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-11-19","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT06177067","phase":"PHASE1","title":"Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-04-19","conditions":"Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":24},{"nctId":"NCT06475235","phase":"PHASE1","title":"Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-10-18","conditions":"Lymphoma, Primary Central Nervous System Lymphoma","enrollment":15},{"nctId":"NCT02315326","phase":"PHASE1, PHASE2","title":"Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-12-08","conditions":"Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)","enrollment":93},{"nctId":"NCT04237103","phase":"PHASE2","title":"Combination of Methotrexate and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2023-05-23","conditions":"Vitiligo","enrollment":32},{"nctId":"NCT04579848","phase":"PHASE4","title":"Methotrexate in Erosive Inflammatory Hand Osteoarthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diakonhjemmet Hospital","startDate":"2021-08-12","conditions":"Hand Osteoarthritis, Erosive Osteoarthritis","enrollment":163},{"nctId":"NCT03760003","phase":"PHASE2","title":"Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2019-08-13","conditions":"Ulcerative Colitis","enrollment":355},{"nctId":"NCT04214626","phase":"PHASE2","title":"R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2020-01-05","conditions":"Diffuse Large B Cell Lymphoma","enrollment":60},{"nctId":"NCT06081400","phase":"NA","title":"Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2024-03-04","conditions":"Desmoid Tumor","enrollment":150},{"nctId":"NCT07156604","phase":"PHASE2","title":"Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-30","conditions":"NSCLC, Neoadjuvant Therapy","enrollment":30},{"nctId":"NCT06673134","phase":"","title":"Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-12-01","conditions":"Crohn Disease","enrollment":100},{"nctId":"NCT05040464","phase":"PHASE3","title":"Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2021-08-26","conditions":"Crohn Disease, Azathioprine, Methotrexate","enrollment":166},{"nctId":"NCT06730542","phase":"PHASE1","title":"Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma","status":"RECRUITING","sponsor":"Juan P. Alderuccio, MD","startDate":"2025-04-17","conditions":"CNS Lymphoma","enrollment":20},{"nctId":"NCT05460832","phase":"PHASE2","title":"Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA","status":"COMPLETED","sponsor":"Modern Biosciences Ltd","startDate":"2022-08-29","conditions":"Rheumatoid Arthritis","enrollment":248},{"nctId":"NCT04737889","phase":"PHASE2","title":"Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2021-01-13","conditions":"Primary Central Nervous System Lymphoma","enrollment":30},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT06753565","phase":"PHASE2","title":"L-carnitine Supplementation in Rheumatoid Arthritis Patients","status":"RECRUITING","sponsor":"German University in Cairo","startDate":"2024-12-31","conditions":"Rheumatoid Arthritis (RA)","enrollment":60},{"nctId":"NCT02305849","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-07-25","conditions":"Rheumatoid Arthritis","enrollment":519},{"nctId":"NCT01393639","phase":"PHASE2","title":"Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09-27","conditions":"Rheumatoid Arthritis","enrollment":323},{"nctId":"NCT03980483","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-05-16","conditions":"Arthritis, Rheumatoid","enrollment":1537},{"nctId":"NCT02706951","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03-23","conditions":"Rheumatoid Arthritis","enrollment":648},{"nctId":"NCT02837978","phase":"PHASE4","title":"The Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months and Long-term Treatment","status":"COMPLETED","sponsor":"Qiang Shu","startDate":"2015-01","conditions":"Arthritis, Rheumatoid","enrollment":150},{"nctId":"NCT02706873","phase":"PHASE3","title":"A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-02-23","conditions":"Rheumatoid Arthritis","enrollment":1002},{"nctId":"NCT05871086","phase":"PHASE2, PHASE3","title":"Coenzyme Q10 in Juvenile Idiopathic Arthritis Patients","status":"UNKNOWN","sponsor":"Nourhan Elsherif","startDate":"2023-05-01","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT03813199","phase":"PHASE2","title":"Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2019-07-04","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT02373813","phase":"PHASE3","title":"Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-20","conditions":"Rheumatoid Arthritis","enrollment":371},{"nctId":"NCT04537689","phase":"PHASE4","title":"Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis","status":"RECRUITING","sponsor":"Singapore General Hospital","startDate":"2020-12-10","conditions":"Plaque Psoriasis","enrollment":40},{"nctId":"NCT04239859","phase":"PHASE4","title":"Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"Singapore General Hospital","startDate":"2024-01","conditions":"Plaque Psoriasis","enrollment":40},{"nctId":"NCT03219437","phase":"PHASE3","title":"A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-07-30","conditions":"Psoriasis","enrollment":104},{"nctId":"NCT02376790","phase":"PHASE3","title":"Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-03-03","conditions":"Psoriatic Arthritis","enrollment":851},{"nctId":"NCT03148860","phase":"PHASE3","title":"Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA","status":"COMPLETED","sponsor":"Dr. Frank Behrens","startDate":"2016-12-15","conditions":"Psoriatic Arthritis","enrollment":186},{"nctId":"NCT02079948","phase":"PHASE2","title":"Inflammation Control For Elders: ICE Study","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2014-02","conditions":"Inflammation, Aging","enrollment":""},{"nctId":"NCT01949116","phase":"PHASE2","title":"Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-01-31","conditions":"HIV Infections","enrollment":176},{"nctId":"NCT03163966","phase":"PHASE2","title":"A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Rottapharm Biotech","startDate":"2017-10-05","conditions":"Rheumatoid Arthritis, DMARD-naive and Early Disease Patients","enrollment":248},{"nctId":"NCT01960855","phase":"PHASE2","title":"A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-10","conditions":"Rheumatoid Arthritis","enrollment":276},{"nctId":"NCT02066389","phase":"PHASE2","title":"A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-03-26","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT02504268","phase":"PHASE3","title":"Effects of Abatacept in Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-09-03","conditions":"Rheumatoid Arthritis","enrollment":994},{"nctId":"NCT02886728","phase":"PHASE3","title":"Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-08-08","conditions":"Rheumatoid Arthritis","enrollment":1252},{"nctId":"NCT00439296","phase":"PHASE1, PHASE2","title":"ABT-751 With Chemotherapy for Relapsed Pediatric ALL","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2006-05-22","conditions":"Recurrent Pediatric ALL, Relapsed Pediatric ALL, Acute Lymphoblastic Leukemia","enrollment":9},{"nctId":"NCT01851707","phase":"PHASE2","title":"A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone","status":"COMPLETED","sponsor":"SecuraBio","startDate":"2013-04","conditions":"Rheumatoid Arthritis","enrollment":322},{"nctId":"NCT02504671","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-23","conditions":"Arthritis, Rheumatoid","enrollment":222},{"nctId":"NCT02799472","phase":"PHASE2","title":"Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-15","conditions":"Arthritis, Rheumatoid","enrollment":39},{"nctId":"NCT01894516","phase":"PHASE2","title":"Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)","status":"COMPLETED","sponsor":"Galapagos NV","startDate":"2013-10-08","conditions":"Rheumatoid Arthritis","enrollment":287},{"nctId":"NCT01888874","phase":"PHASE2","title":"Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)","status":"COMPLETED","sponsor":"Galapagos NV","startDate":"2013-07-17","conditions":"Rheumatoid Arthritis","enrollment":599},{"nctId":"NCT03515200","phase":"PHASE1","title":"Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2018-04-20","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission","enrollment":12},{"nctId":"NCT00290498","phase":"PHASE2","title":"Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-08-01","conditions":"Lymphoma","enrollment":67},{"nctId":"NCT02699710","phase":"PHASE1","title":"Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2015-09-03","conditions":"Healthy Volunteer","enrollment":50},{"nctId":"NCT02831855","phase":"PHASE4","title":"Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-09-01","conditions":"Rheumatoid Arthritis","enrollment":694},{"nctId":"NCT01469013","phase":"PHASE2","title":"Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-11","conditions":"Arthritis, Rheumatoid","enrollment":145},{"nctId":"NCT03028467","phase":"PHASE1, PHASE2","title":"Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-24","conditions":"Arthritis, Rheumatoid","enrollment":15},{"nctId":"NCT01362530","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09-13","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":307},{"nctId":"NCT01039688","phase":"PHASE3","title":"Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-01","conditions":"Arthritis, Rheumatoid","enrollment":956},{"nctId":"NCT01741493","phase":"PHASE1","title":"A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-11","conditions":"Rheumatoid Arthritis","enrollment":67},{"nctId":"NCT00245037","phase":"PHASE1, PHASE2","title":"Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2005-06","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":147},{"nctId":"NCT01900431","phase":"PHASE2","title":"Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-10","conditions":"Uveitis","enrollment":58},{"nctId":"NCT02480946","phase":"PHASE1","title":"Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Modern Biosciences Ltd","startDate":"2015-07","conditions":"Arthritis, Rheumatoid","enrollment":105},{"nctId":"NCT02764515","phase":"PHASE4","title":"Kunxian for the Treatment of Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2015-09","conditions":"Rheumatoid Arthritis","enrollment":428},{"nctId":"NCT02543931","phase":"PHASE1","title":"Curcuma Longa L in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"University of Arizona","startDate":"2015-11","conditions":"Rheumatoid Arthritis","enrollment":3},{"nctId":"NCT01034137","phase":"PHASE3","title":"A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Rheumatoid Arthritis","enrollment":317},{"nctId":"NCT02660684","phase":"PHASE4","title":"Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2008-02","conditions":"Graft Versus Host Disease","enrollment":39},{"nctId":"NCT00189878","phase":"PHASE2","title":"A Study of the Use of Methotrexate in the Treatment of Chronic Idiopathic Urticaria","status":"TERMINATED","sponsor":"Barnsley Hospital","startDate":"2003-08","conditions":"Urticaria","enrollment":3},{"nctId":"NCT02271971","phase":"NA","title":"Effect of Vitamin D Supplementation on Metabolic Parameters of Patients With Psoriasis","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2014-10","conditions":"Psoriasis, Metabolic Syndrome, Vitamin D Deficiency","enrollment":39},{"nctId":"NCT00717808","phase":"PHASE1","title":"Effects of Tranilast on Pharmacokinetics of Methotrexate (MTX) in Patients With Rheumatoid Arthritis (RA)","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2008-09","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT01164579","phase":"PHASE2","title":"Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-10","conditions":"Rheumatoid Arthritis","enrollment":109},{"nctId":"NCT01488253","phase":"PHASE2","title":"Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants","status":"TERMINATED","sponsor":"The Korean Society of Blood and Marrow Transplantation","startDate":"2012-01","conditions":"Acute Leukemia in Remission, Myelodysplastic Syndromes, Leukemia, Myeloid, Chronic-Phase","enrollment":3},{"nctId":"NCT01090570","phase":"PHASE1","title":"Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate","status":"WITHDRAWN","sponsor":"Plexxikon","startDate":"2010-05","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT02373579","phase":"PHASE2","title":"Effect of Omega-3 Fatty Acids on Methotrexate Induced Hepatotoxicity in Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Nancy Samir Elbarbary","startDate":"2012-06","conditions":"Acute Lymphoblastic Leukemia","enrollment":70},{"nctId":"NCT00264537","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2005-12","conditions":"Rheumatoid Arthritis","enrollment":637},{"nctId":"NCT00361335","phase":"PHASE3","title":"A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2006-09","conditions":"Rheumatoid Arthritis","enrollment":643},{"nctId":"NCT00810199","phase":"PHASE3","title":"A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":556},{"nctId":"NCT00264550","phase":"PHASE3","title":"An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2005-12","conditions":"Rheumatoid Arthritis","enrollment":444},{"nctId":"NCT01185288","phase":"PHASE4","title":"A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":309},{"nctId":"NCT01185301","phase":"PHASE3","title":"Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-10","conditions":"Early Rheumatoid Arthritis","enrollment":395},{"nctId":"NCT01001208","phase":"PHASE3","title":"The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-11","conditions":"Psoriasis","enrollment":478},{"nctId":"NCT00003536","phase":"PHASE2","title":"Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer","status":"WITHDRAWN","sponsor":"Burzynski Research Institute","startDate":"","conditions":"Stage IV Breast Cancer, Recurrent Breast Cancer","enrollment":""},{"nctId":"NCT01668641","phase":"PHASE2","title":"Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Galapagos NV","startDate":"2012-05","conditions":"Rheumatoid Arthritis","enrollment":91},{"nctId":"NCT01450982","phase":"PHASE1","title":"A Study to Investigate How JNJ-38518168 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-06","conditions":"Rheumatoid Arthritis","enrollment":20},{"nctId":"NCT00941707","phase":"PHASE2","title":"An Efficacy and Safety Study of JNJ-38518168 in Adult Participants With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-02","conditions":"Rheumatoid Arthritis","enrollment":86},{"nctId":"NCT00787761","phase":"PHASE2","title":"Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer","status":"COMPLETED","sponsor":"Northside Hospital, Inc.","startDate":"2007-04","conditions":"Myeloproliferative Disorders, Kidney Cancer, Leukemia","enrollment":24},{"nctId":"NCT01384422","phase":"PHASE2","title":"Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Galapagos NV","startDate":"2011-06","conditions":"Rheumatoid Arthritis","enrollment":36},{"nctId":"NCT01329991","phase":"PHASE1","title":"Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving Methotrexate","status":"COMPLETED","sponsor":"Plexxikon","startDate":"2011-05","conditions":"Rheumatoid Arthritis","enrollment":26},{"nctId":"NCT00508768","phase":"PHASE1","title":"A Study of Oral SCIO-469 Pharmacokinetics (Study of a Drug in the Body to Watch How the Drug is Absorbed, Distributed, Metabolized and Eliminated Over a Period of Time) in the Body of Female Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Scios, Inc.","startDate":"","conditions":"Rheumatoid Arthritis","enrollment":16},{"nctId":"NCT01211249","phase":"PHASE2","title":"GLPG0259 in Methotrexate-refractory Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Galapagos NV","startDate":"2010-10","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT00089921","phase":"PHASE2","title":"SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate","status":"COMPLETED","sponsor":"Scios, Inc.","startDate":"2004-07","conditions":"Arthritis, Rheumatoid","enrollment":302},{"nctId":"NCT00525213","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 When Added to Methotrexate","status":"COMPLETED","sponsor":"OxyPharma","startDate":"2007-10","conditions":"Rheumatoid Arthritis","enrollment":224},{"nctId":"NCT00235820","phase":"PHASE3","title":"Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Abbott","startDate":"2005-07","conditions":"Psoriasis","enrollment":271}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Methotrexate capsules","genericName":"Methotrexate capsules","companyName":"Centocor, Inc.","companyId":"centocor-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methotrexate inhibits dihydrofolate reductase, blocking the synthesis of purines and pyrimidines required for DNA replication and cell division. Used for Acute lymphoblastic leukemia (ALL), Breast cancer, Lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}